1. Home
  2. INGN vs IMUX Comparison

INGN vs IMUX Comparison

Compare INGN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.78

Market Cap

173.5M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$15.06

Market Cap

200.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
IMUX
Founded
2001
2016
Country
United States
United States
Employees
N/A
66
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.5M
200.4M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
INGN
IMUX
Price
$6.78
$15.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$11.25
$36.00
AVG Volume (30 Days)
310.3K
219.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
38.00
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$0.51
52 Week High
$9.13
$15.77

Technical Indicators

Market Signals
Indicator
INGN
IMUX
Relative Strength Index (RSI) 61.30 66.87
Support Level $6.59 $0.74
Resistance Level $7.12 $15.77
Average True Range (ATR) 0.24 1.13
MACD 0.07 -0.04
Stochastic Oscillator 92.22 87.65

Price Performance

Historical Comparison
INGN
IMUX

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: